Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Roles at http://pharmaceuticalintelligence.com

Editor, Nanotechnology for Drug Delivery

Research Category OWNER:

Nanotechnology for Drug Delivery – Investigator Initiated New Research Category

Expert, Author, Writer:

Tilda Barliya, PhD

tildabarliya@gmail.com

Personal Bio

Specialties: Oncology, Cell biology, Ophthalmology and Nanotechnology.

I am a research scientist at the Department of Ophthalmology at the Rabin Medical Center.

• I am a highly skilled cancer cell biologist with strong background and interest in nanotechnology for drug delivery.  I completed my first Post-doctoral fellowship at Weill Cornell Medical Center in NYU exploring the preventative effects of different chemotherapeutic drugs on breast cancer progression. Thereafter I conducted a second post-doc at UNC in field of nanotechnology exploring new drug delivery platforms and performed as an active editor and author in several scientific blogs. Few years ago, I joined the ophthalmology research team at the Rabin Medical Center exploring new application of nanotechnology in eye diseases as well as understanding the underlying cause of different retinal diseases.
• I bring a wide-spectrum of expertise in multidisciplinary field of nanotechnology oncology as well as ophthalmology.

Professional in the fields of biotechnology, nanotechnology and medical devices. PhD in tumor and vascular biology from Sackler School of Medicine, Tel-Aviv University, with 10 years of experience in Cancer research. Explored and developed the antiangiogenic properties of Hypericin. Drug entered Phase I clinical trials for the treatment of brain tumors.

Expertise in the following fields:

• Tumor cell biology (In vivo and In vitro: WB, IF, ELISA, IP, RT-PCR,SEM)
• Vascular biology
• Imaging tools: Tumor imaging in vivo; live tumor visualization ,microscopy
• Nanoparticles fabrication (PLGA, PEG)
• Rational drug design
• Drug encapsulation in nanoparticles and analysis of drug release profile (HPLC).

Educational and Professional History

Rabin Medical Center-Beilinson Campus, Israel                  present

Research Project Manager: supervised by Prof. Dov Weinberger, head of the Ophthalmology department.

• Developing new applications of surgical sealants for different eye diseases.
• Developing ferro-based nano vehicles for eye surgeries.
• Evaluating the feasibility of magnetic-remote control over ferro-based nano vehicles for eye surgeries.
• Evaluating the feasibility of a new medical device for IOP

UNC, Chapel Hill, NC, USA                                      2010-Early 2012  

Post Doctoral Fellow:    Supervised by Prof. Joseph DeSimone.

Research Subject- Study and evaluate Chemo-loaded NPs of different size and shape for cancer models.

• Nanoparticle fabrication, drug encapsulation and encapsulation analysis
• In vitro release studies of encapsulated drugs
• In vivo pharmacokinetics (PK) studies
• In vivo Imaging – Found a novel approach for tumor imaging using the PLGA-dye polymer
• An academic lab using a business platform with the appropriate Q-meetings and internal lab reports.
• Writing SOP for and conducted research under GMP conditions.

Weill Cornell Medical College, NYC, USA               2007-2010

Post Doctoral Fellow:   Supervised by Dr. Meena Katdare

Research Subject- Study mutagens and carcinogens associated with mammary tumorgenesis pathways.

• Susan G. Kolmen for the cure “Scholar-In-Training Award” for the AAC Frontier in Cancer Prevention Research Conference   (2008)
• Supervised a group of PhD students, surgery residents and pre-Med students
• Expert in Tumor cell biology and tissue culture
• Tumor-animal studies and drug administration

Tel-Aviv University, Tel-Aviv, Israel                             2003-2007

PhD in Medical Science/ Cell Biology: Supervised by Dr. Gad Lavie

Department of Cell Biology, Sackler School of Medicine

PhD thesis: “The mechanism of inhibition of angiogenesis by Hypericin”

• Found the antiangiogenic properties of Hypericin. Hypericin was re-patented by HyBiopharma and enter phase I clinical trials for glioblastoma. HyBiopharma www.hybiopharma.com
• A research assistant for a project on Multiple Sclerosis (MS)  in the Sheba   Medica   Center, Tel – Hashomer, Ramat Gan.
• First place awarder at the Sheba Medical Center Research day (2004)
• Travel fellowship by Michaelson Club Symposium for Eye Research (2007)
•  Supervised and guided master students in their projects.

Tel-Aviv University, Tel-Aviv, Israel                            2000-2002

M.Sc in Medical Science/ Cell Biology: Supervised by Dr. Lavie

Department of Cell Biology, Sackler School of Medicine.

•  Graduated with honor
•  Research assistant for a project on Multiple Sclerosis (MS)  in the Sheba  Medical Center, Tel – Hashomer, Ramat Gan.
•  Volunteered as a tutor for students with learning difficulties.

Tel -Aviv University, Tel-Aviv, Israel                       1998-2000

 B.Sc in Life Science

•  Volunteered as a tutor for students with learning difficulties.

Professional work experience

2000- 2007 –             Sheba Medical Center- Tel Hashomer           

Acquired knowledge while being a research assistant in a clinical trial for Multiple Sclerosis patients in the Sheba Medical Center (Israel). This experiment included producing T-cell vaccinations, characterizing them on their TCR vβ and gene profiles.

• In vitro; T cell receptor sequencing

Awards and Scholarships

2004 – First place awarde at the Sheba Medical Center Research day

2007 – Travel fellowship by Michaelson Club Symposium for Eye Research

2008 – Susan G. Kolmen for the cure “Scholar-In-Training Award” for the AACR Frontier in Cancer Prevention Research Conference

Workshops

2004 – Tel Aviv University Cancer Research Center, Cefar Blum, Israel

2004 – Sheba Medical Center Research day

2005 – Michaelson Club Symposium for Eye Research, Belgium

2006 – Israeli Eye Research, Neve Ilan, Israel

2007 – Israeli Eye Research, Neve Ilan, Israel

2007 – Tel Aviv University Cancer Research Center, Israel

2007 – Michaelson Club Symposium for Eye Research, Baltimore USA.

2008 – AACR Frontiers in Cancer Prevention Research Conference, Washington DC,

2010 – 101 annual AACR meeting, Washington DC, USA

Publications

Barliya T., Mandel M., Livnat T., Weinberger D and Lavie G. “Degradation of HIF-1alpha Under Hypoxia Combined with Induction of Hsp90 Polyunbiquitination in Cancer Cells by Hypericin; a Unique Cancer Therapy”. PLoS ONE, 6(9) Sep 19, 2011.

Barliya T and Katdare M. “Preventive efficacy of curcumin on ENU-induced carcinogenic transformation of Apc^Min/+ mammary epithelial (MinMG) cells established from Apc^Min/+ mouse”. 101 Annual AACR meeting will be held in April 2010. Abstract.

Brooks R*., Barliya T.,*, Wynne N and Katdare M. “APC gene mutation and its role in breast carcinogenesis: Curcumin as a chemopreventive phytochemical”. J Am Coll Sur October 2009. Abstract. *co-authors

Barliya T., Gall-Troselj K., Crawford C. and Katdare M. “Curcumin downregulates IL-8 in DCIS breast cancer cells; correlation between tumorgenecity and inflammation”. 7^th Annual AACR conference on Frontiers in Cancer Prevention Research, Nov. 2008; p38 (A34). Abstract

Mandel M, Achiron A, Tuller T, Barliya T, Rechavi G, Amariglio N, Loewenthal R, Lavie G. Clone clusters in autoreactive CD4 T-cell lines from probable multiple sclerosis patients form disease-characteristic signatures. Immunology 2009 Oct;128(2):287-300.

Lavie G, Barliya T et al. Competitive quenching”: a mechanism by which perihydroxylated perylenequinone photosensitizers can prevent adverse phototoxic damage caused by verteporfin during photodynamic therapy. Photochem Photobiol. 2007 Sep-Oct;83(5):1270-7.

Hazan Z, et al.Effective prevention of microbial biofilm formation on medical devices by low-energy surface acoustic waves. Antimicrob Agents Chemother. 2006 Dec;50(12):4144-52. Epub 2006 Aug 28.

Lavie G. et al. Anti-angiogenic activities of hypericin in vivo: potential for ophthalmologic applications. Angiogenesis. 2005;8(1):35-42.

Weinberger D. et al. Competitive quenching: a possible novel approach in protecting RPE cells from damage during PDT. Curr Eye Res. 2005;30(4): 269-277.

Achiron A.et al. T cell vaccination in multiple sclerosis relapsing-remitting nonresponders patients. Clin Immunol. 2004;113(2):155-160.

Languages

Hebrew – native

English – fluent

French – Basic